Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
JAK inhibitors
Pharma
Incyte expects Opzelura to cross $1B in 2026
The topical eczema and vitiligo treatment is enjoying a boost stemming from a recent Medicaid rebate settlement.
Angus Liu
Jul 29, 2026 10:30am
Sanofi inks $1.5B deal for Sino Biopharm's novel asset
Mar 4, 2026 3:00am
Incyte expands awards program to hidradenitis suppurativa
Nov 6, 2025 10:00am
New Incyte CEO takes 'fresh look' at business, outlines BD plan
Aug 4, 2025 11:16am
Alfasigma's JAK inhibitor Jyseleca scores in phase 3 trial
Jul 29, 2025 8:50am
China biotech deals, Takeda, LaNova—Fierce Pharma Asia
Jul 18, 2025 9:04am
